Cancer Research Wales and Leukaemia and Lymphoma Research. 1 CLL has a heterogeneous clinical course with a spectrum of diseases ranging from indolent disease not requiring treatment to aggressive disease that is fatal. 2 At present there are no curative therapies for CLL, with the possible exception of allogeneic stem cell transplantation (SCT) 3 , but this option has high morbidity and mortality rates, and is only suitable for a small minority of patients.
Over the last 20 years monoclonal antibodies, most noticeably alemtuzumab and rituximab have emerged as new therapeutics in CLL. 4, 5 The chimeric anti-CD20 monoclonal antibody rituximab has brought about significant improvements in response rates, progression-free survival and overall survival when used in combination with fludarabine and cyclophosphamide in previously untreated patients. 6 , 7 Alemtuzumab has been used as monotherapy as well as in combination with chemotherapies, high dose steroids and other monoclonal antibodies and has proved to be extremely useful in patients with p53 mutations/deletions, as it appears to be cytotoxic via a p53-independent mechanism. 8 However, it is highly immunosuppressive 9 and so there is a need for newer less toxic, more effective and targeted therapeutic agents both for relapsed and treatment naïve patients with comorbidities.
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Blinatumomab is a bi-specific single chain antibody construct classified as bi-specific T-cell engager (BiTE ® ). It is formed by the recombinant fusion of an anti-CD3 single chain variable fragment (scFV) with an anti-CD19 scFV via a short peptide linker.
These bi-specific antibodies can recruit immune effector cells to the tumor cell 4 surface and promote immune synapse formation. 11 Blinatumomab has already shown encouraging clinical activity; in a phase II trial 80% of relapsed acute lymphoblastic leukemia patients achieved a complete molecular response 12 and in a phase I study in relapsed non-Hodgkin's lymphoma (NHL) clinical responses were seen both in patients with indolent as well as aggressive B-NHL. 13, 14 However, given the wellknown T-cell dysfunction seen in CLL, blinatumomab may be less effective in this disease. [15] [16] [17] In the current study, we provide a detailed analysis of the mechanism of action of blinatumomab-induced cytotoxicity in CLL. Our findings are consistent with a model that relies upon the sequential activation of T-cells and CLL cells and demonstrate that blinatumomab retains efficacy even in the presence of CLL activation and prosurvival signals. Given these data, this approach represents a novel and promising therapeutic strategy for the treatment of CLL and potentially other lymphoid malignancies.
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Methods

Blood samples from CLL patients
28 CLL patients (aged 53-83 years) were studied with full ethical approval and all patient blood samples obtained with informed consent (see supplementary methods).
The majority of the assays were performed on fresh samples from treatment naïve patients, except in Figure 1 where samples from patients who had received standard chemotherapy treatment were also tested.
Antibodies and flow cytometry
A full list of the antibodies used can be found in the supplemental methods online.
Blinatumomab (MT103, AMG103) was provided by Amgen Inc. (Munich, Germany).
T-cells were identified using CD4 and CD8 markers, while CLL cells were CD5 + CD4 -CD8 -(>99% CD19 positive).
Cell culture
PBMCs were incubated in RPMI 1640 supplemented with 5% AB serum (AB media) for 3-7 days. Blinatumomab was added to PBMC cultures at 10 or 100ng/ml. Human T-cell activator CD3/CD28 dynabeads (Invitrogen) were added at 1x10 5 beads/1x10
6 Cytokines in tissue culture supernatants were measured using a Human Th1/Th2 11plex RTU Flowcytomix kit (eBioscience) for simultaneous detection of 11 cytokines.
Intracellular cytokine staining and the determination of CD107 and Granzyme B expression PBMC were cultured (3 days) with 10ng/ml blinatumomab, before treatment with golgi plug and golgi stop (BD biosciences), and incubation with an anti-CD107
antibody (5 hours at 37°C). Intracellular expression of granzyme B or IFN-γ and TNF-α in CD4 or CD8 T cells was measured by flow cytometry.
Absolute counts of T-cells and CLL cells
PBMC samples that had been treated with or without blinatumomab (7 days) were surface stained with antibodies against Annexin V, CD5, CD8 and CD4. Absolute counts were determined by flow cytometry using Cytocount beads (Dako, Stockport, UK).
Flow cytometry-based cytotoxicity assay
Mouse fibroblast cells transfected with CD40L (TL(CD40L)) and non-transfected cells (NTL) were cultured as previously described. 21 For co-cultures, irradiated (80 Gy) NTL or TL(CD40L) cells were seeded into a 48-well plate, allowed to adhere before addition of CLL PBMC and blinatumomab (10 or 100 ng/ml) for 7 days. CLL PBMCs were removed from the surface of the fibroblast monolayer, and analysed by flow cytometry (Annexin V, CD5, CD8 and CD4).
Immunofluorescence labelling for microscopy
Purified T-cells and CLL cells were labeled with 15mM red CFSE (Invitrogen) and and 10 mM Green CFSE (Invitrogen) respectively. Labeled cells were put into culture at a ratio of 1 effector T-cell to every 10 target CLL cells for 12 hours. Further details 7 of phase contrast and confocal microscopy can be found in the supplementary methods.
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Results
Blinatumomab induces the expansion of T-cells and a reduction in CLL cells in primary CLL samples
The effect of blinatumomab on PBMC cultures from 15 CLL patients was measured by determining absolute counts of T cells and CLL cells after 7 days. Both treatment naïve (n=10), and previously treated (n=5) patients were tested. Cultures treated with blinatumomab had significantly higher absolute numbers of CD4 + (P=0.01) and CD8 + T-cells (P=0.01) after 7 days when compared to untreated controls ( Figure 1A and B). By contrast there was a significant reduction in the absolute numbers of CLL cells in the same cultures suggesting a cytotoxic effect against leukemic cells (P=0.002; Figure 1C ). In our system, spontaneous apoptosis of CLL cells averaged 45% (data not shown), however blinatumomab increased apoptosis to an average of 75% (data not shown, Figure 1C ). This apparent cytotoxic effect on CLL cells was indistinguishable between treatment naïve, and previously treated patients ( Figure   1C ).
Cultures treated with an anti-CD3 antibody (at the same molar concentration as blinatumomab) also demonstrated significant increases in absolute T-cell numbers ( Figure 1A ). However in sharp contrast to blinatumomab, the anti-CD3 antibody induced a significant increase in CLL cell numbers ( Figure 1C ). It is possible that CD3 triggering in the absence of co-stimulation is incapable of activating cytotoxicity against CLL, however cultures treated with anti-CD3/anti-CD28 beads showed similar results to those treated with CD3 alone; a significant increase in T-cells ( Figure 1A and 1B) and a trend towards increased CLL cell number ( Figure 1C ) after treatment. Interestingly in blinatumomab treated cultures, there was an inverse correlation between the change in T-cell numbers and % change in CLL cell numbers (Supplemental Figure 1A) suggesting that the T-cell response was important to the cytotoxic effects observed. This was not the case with either anti-CD3 or anti-
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CD3/anti-CD28 treated cultures (Supplemental Figure 1B and C); these cultures showed a trend towards increased T-cell numbers being associated with increased CLL numbers (Supplemental Figure 1B and C).
Taken together these results suggest that blinatumomab activates T-cells in PBMC derived from primary CLL patients in a manner similar to anti-CD3 antibody or CD3/CD28 beads. However, unlike these stimuli, it appears that blinatumomab promotes T cell mediated cytotoxicity of CLL cells.
Blinatumomab induces CLL cell death by apoptosis that is enhanced in the presence of CD40L
To The effects of blinatumomab were additionally tested in a co-culture system with a CD40L transfected fibroblast cell line to promote cell survival [22] [23] [24] . [18] [19] [20] In keeping with previous findings. 21 A previous study had demonstrated an expansion of T cells with an effector memory (EM) phenotype in a patient with non-Hodgkins lymphoma that had responded to blinatumomab treatment. 16 It was of interest to determine whether blinatumomab had a similar effect on primary samples from CLL cells. Blinatumomab induced a 
Blinatumomab induces clustering of CLL cells around T-cells
There was no obvious difference in the capacity of blinatumomab to induce T-cell activation based on several criteria (proliferation, cytokine release or cytotoxic In this study we present detailed in vitro evidence that the bi-specific antibody (blinatumomab), directed against CD3 and CD19, can activate and induce the proliferation of T-cells from CLL patients in situ. By several criteria (Ki67 expression, cytokine secretion, cytotoxic granule formation), blinatumomab appeared to have comparable potency to anti-CD3/anti-CD28 beads in activating functional T-cells. Our study showed that there was preferential expansion of an effector memory (EM) phenotype in both the CD4 + and CD8 + T-cell compartments; a phenomenon previously reported in NHL patients treated with blinatumomab. 13 Both CD4 + and CD8 + T-cells had increased intracellular expression of granzyme B and the degranulation marker surface CD107. This suggests that both T-cell subsets can be redirected to become cytolytic against CLL cells in the presence of blinatumomab.
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Although cytotoxic CD4 + T-cells are relatively rare in healthy subjects, 30 an expanded population of CD4 + perforin + T-cells with an effector memory phenotype has been described in CLL patients. 31 Our study used 3-7 day cultures of PBMC treated with blinatumomab. While these assays allowed the investigation of the activating effects of blinatumomab on T cells, it is possible that our assays may have missed the rapid killing of CLL cells (within 4-24 hours) that has been demonstrated by previous studies 32, 33 . This direct cytotoxicity did not require activation or proliferation of T cells, and involved caspase activation. 33 However even with the reported rapid effects of blinatumomab, we were able to show significant cytotoxicity against CLL cells at day 7 in the majority of patients tested. chemotherapy, who will have low T cell numbers post-therapy. The rapid mode of killing induced by blinatumomab may be ineffective in these cases. 32 In our assay system, which measured the activation and expansion of T cells, the numbers of T cells were important; there was an inverse correlation between change in % CLL cell Although similar cytokine release profiles were seen after blinatumomab treatment, in this scenario it was associated with significantly reduced survival of CLL cells.
Therefore our data suggest that T-cell activation and pro-inflammatory cytokine release are insufficient to induce CLL cell death. Rather, the T-cell:CLL cell conjugation mediated by blinatumomab is a critical additional step in promoting the redirected secretion of cytotoxic molecules towards the surface of the tumor cell and ultimately CLL cell death. Although detailed investigation of immunological synapses was not performed in this study, it was possible that the bridging effect of blinatumomab was able to bypass the defects in immune synapse formation previously reported with CLL cells. 16 Our findings have potentially important implications for adoptive immunotherapy of CLL because they suggest that also exhibiting a p53 deletion. It is of considerable interest that there was no significant reduction in the ability of blinatumomab to kill CLL cells from these patients when compared to chemo-immunotherapy naïve CLL cells (data not shown).
These data indicate that the mechanism of action of blinatumomab is very different to other therapeutic agents and is probably p53-independent.
Our in vitro findings support a model in which blinatumomab promotes a forced conjugate between T-cells and CLL cells (Supplementary Figure 8) . This is consistent with previous studies on blinatumomab that have investigated mechanisms of cytotoxicity against lymphoma cell lines. 4848 Similar observations demonstrating the cytotoxic effects of T cell:CLL cell conjugation have also been made using HLA/peptide/CD20 antibody constructs. 4949 Since CLL cells are required for T cell activation by blinatumomab (Supplementary Figure 7) , it is likely that conjugate formation is required at both the activation and effector phases. We have used confocal microscopy to generate a model where 11 CLL cells can cluster around a single T cell. Moreover we show that T cell activation is accompanied by CLL cell activation, and that may render the CLL cells more susceptible to cytotoxicity. Importantly, the effector T cells generated can kill CLL cells even in the presence of pro-survival co-culture conditions.
In conclusion, blinatumomab has the ability to overcome the immunodeficiency in 
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